Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Tesla’s vote wasn’t about pay. It was about who really runs the company

View original at finance.yahoo.com
Tesla’s vote wasn’t about pay. It was about who really runs the company At Tesla’s 2025 Annual Meeting, something significant and important happened…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Tesla shareholders voted according to what they believed was in their financial interest and would create long-term value, exercising independent judgment rather than following proxy advisory firms

    80% confidence
  • Tesla's compensation plan is excessive and unconventional

    80% confidence
  • The days of blind deference to advisory firms that fail to appreciate the complexities of modern-day businesses are coming to an end

    80% confidence
  • The 2025 CEO Performance Award has no salary, no cash bonus, and no payout unless extraordinary milestones are reached

    80% confidence
  • Derivative lawsuits are too often exploited as vehicles for opportunistic litigation, enriching plaintiff lawyers at the expense of shareholders

    80% confidence
  • Proxy advisory tools are increasingly misaligned with the realities of the modern economy and cannot meaningfully assess companies operating at the frontier of technological transformation

    80% confidence
  • Shareholders have affirmed the substance of the 2018 CEO Performance Award on three separate occasions, each with support exceeding 75% of votes cast

    80% confidence
  • Even excluding shares held by Elon Musk, the proposals passed by over 70%, well over the required majority threshold

    80% confidence
  • Tesla operates across artificial intelligence, robotics, autonomous solutions, energy systems, semiconductor development, and advanced manufacturing

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com